Literature DB >> 20138814

Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry.

Maren I Blonk1, Bart C van der Nagel, Liesbeth S Smit, Ron A A Mathot.   

Abstract

A sensitive and specific method using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the determination of levetiracetam (LEV) in plasma of neonates. A plasma aliquot of 50 microl was deproteinized by addition of 500 microl methanol which contained 5 microg/ml UCB 17025 as an internal standard. After centrifugation, 50 microl of supernatant was diluted with 1000 microl of 0.1% formic acid-10 mM ammonium formate in water (pH 3.5) (mobile phase solution A) and 2 microl was injected onto the UPLC-system. Compounds were separated on a Acquity UPLC BEH C(18) 2.1 mm x 100 mm column using gradient elution with mobile phase solution A and 0.1% formic acid in methanol (mobile phase solution B) with a flow rate of 0.4 ml/min and a total runtime of 4.0 min. LEV and the internal standard were detected using positive ion electrospray ionization followed by tandem mass spectrometry (ESI-MS/MS). The assay allowed quantification of LEV plasma concentrations in the range from 0.5 microg/ml to 150 microg/ml. Inter-assay inaccuracy was within +/-2.7% and inter-assay precision was less than 4.5%. Matrix effects were minor: the recovery of LEV was between 97.7% and 100%. The developed method required minimal sample preparation and less plasma sample volume compared to earlier published LC-MS/MS methods. The method was successfully applied in a clinical pharmacokinetic study in which neonates received intravenous administrations of LEV for the treatment of neonatal seizures. Copyright 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138814     DOI: 10.1016/j.jchromb.2010.01.037

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

Review 1.  Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy.

Authors:  Jason Tan; Vanessa Paquette; Marc Levine; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

2.  A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures.

Authors:  Joanie K Tulloch; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

3.  Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry.

Authors:  Li-Ling Yeap; Yoke-Lin Lo
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

4.  Multivariate optimization of mebeverine analysis using molecularly imprinted polymer electrochemical sensor based on silver nanoparticles.

Authors:  Azizollah Nezhadali; Golnar Ahmadi Bonakdar
Journal:  J Food Drug Anal       Date:  2018-06-06       Impact factor: 6.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.